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Reversible and formaldehyde-mediated covalent binding of a bis-amino
mitoxantrone analogue to DNA
Abstract
The ability of a bis-amino mitoxantrone anticancer drug (named WEHI-150) to form covalent adducts with
DNA, after activation by formaldehyde, has been studied by electrospray ionisation mass spectrometry and
HPLC. Mass spectrometry results showed that WEHI-150 could form covalent adducts with
d(ACGCGCGT)2 that contained one, two or three covalent links to the octanucleotide, whereas the control
drugs (daunorubicin and the anthracenediones mitoxantrone and pixantrone) only formed adducts with one
covalent link to the octanucleotide. HPLC was used to examine the extent of covalent bond formation of
WEHI-150 with d(CGCGCG)2 and d(CG5MeCGCG)2. Incubation of WEHI-150 with d(CG5MeCGCG)2
in the presence of formaldehyde resulted in the formation of significantly greater amounts of covalent adducts
than was observed with d(CGCGCG)2. In order to understand the observed increase of covalent adducts
with d(CG5MeCGCG)2, an NMR study of the reversible interaction of WEHI-150 at both CpG and
5MeCpG sites was undertaken. Intermolecular NOEs were observed in the NOESY spectra of
d(ACGGCCGT)2 with added WEHI-150 that indicated that the drug selectively intercalated at the CpG sites
and from the major groove. In particular, NOEs were observed from the WEHI-150 H2,3 protons to the H1′
protons of G3 and G7 and from the H6,7 protons to the H5 protons of C2 and C6. By contrast,
intermolecular NOEs were observed between the WEHI-150 H2,3 protons to the H2′′ proton of the 5MeC3
in d(CG5MeCGCG)2, and between the drug aliphatic protons and the H1′ proton of G4. This demonstrated
that WEHI-150 preferentially intercalates at 5MeCpG sites, compared to CpG sequences, and predominantly
via the minor groove at the 5MeCpG site. The results of this study demonstrate that WEHI-150 is likely to
form interstrand DNA cross-links, upon activation by formaldehyde, and consequently exhibit greater
cytotoxicity than other current anthracenedione drugs.
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                     WEHI-150                                    WEHI-150 reversibly bound with DNA  
 
 
The ability of the anthracenedione anticancer drug WEHI-150 to form covalent adducts with 
DNA, after activation by formaldehyde, has been studied by mass spectrometry, HPLC and 
NMR spectroscopy.   
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Abstract 
The ability of a bis-amino mitoxantrone anticancer drug (named WEHI-150) to form covalent 
adducts with DNA, after activation by formaldehyde, has been studied by electrospray 
ionisation mass spectrometry and HPLC.  Mass spectrometry results showed that WEHI-150 
could form covalent adducts with d(ACGCGCGT)2 that contained one, two or three covalent 
links to the octanucleotide, whereas the control drugs (daunorubicin and the anthracenediones 
mitoxantrone and pixantrone) only formed adducts with one covalent link to the 
octanucleotide.  HPLC was used to examine the extent of covalent bond formation of WEHI-
150 with d(CGCGCG)2 and d(CG5MeCGCG)2.  Incubation of WEHI-150 with 
d(CG5MeCGCG)2 in the presence of formaldehyde resulted in the formation of significantly 
greater amounts of covalent adducts than was observed with d(CGCGCG)2.  In order to 
understand the observed increase of covalent adducts with d(CG5MeCGCG)2, an NMR study 
of the reversible interaction of WEHI-150 at both CpG and 5MeCpG sites was undertaken.  
Intermolecular NOEs were observed in the NOESY spectra of d(ACGGCCGT)2 with added 
WEHI-150 that indicated that the drug selectively intercalated at the CpG sites and from the 
major groove.  In particular, NOEs were observed from the WEHI-150 H2,3 protons to the 
H1' protons of G3 and G7 and from the H6,7 protons to the H5 protons of C2 and C6.  By 
contrast, intermolecular NOEs were observed between the WEHI-150 H2,3 protons to the 
H2" proton of the 5MeC3 in d(CG5MeCGCG)2, and between the drug aliphatic protons and the 
H1' proton of G4.  This demonstrated that WEHI-150 preferentially intercalates at 5MeCpG 
sites, compared to CpG sequences, and predominantly via the minor groove at the 5MeCpG 
site.  The results of this study demonstrate that WEHI-150 is likely to form interstrand DNA 
cross-links, upon activation by formaldehyde, and consequently exhibit greater cytotoxicity 





Anthracyclines (e.g. daunorubicin, see Figure 1) are an important class of anticancer agents 
that continue to play a significant role in the treatment of cancer.1-3  However, their clinical 
use is limited by their cardiotoxicity.4  This dose-limiting toxicity has promoted the search for 
new anthracenedione, and aza-anthracenedione derivatives, with comparable cytotoxicity but 
lower cardiotoxicity.  Mitoxantrone and pixantrone (see Figure 1) are two examples of 
synthetic second generation anthracycline derivatives that exhibit significantly lower 
cardiotoxicity but maintain potent anticancer activity.5-8  Similar to the parent anthracyclines, 
the anthracenedione analogues can bind DNA by intercalation between the base pairs and 
thereby induce their cytotoxic effect through the impairment of topoisomerase II.9-11  In 
addition, in an attempt to develop an alternative pathway to anticancer activity, 
anthracenediones have also been used to target G-quadruplex DNA structures.12,13  Recently, 
it has been demonstrated that daunorubicin, mitoxantrone and pixantrone can form drug-DNA 
covalent adducts at the N-2 amino groups of guanine nucleotides after activation by 
formaldehyde.14-16  As the anthracenedione analogues are more cytotoxic to cells and solid 
tumours that produce higher levels of formaldehyde, it has been proposed that covalent bond 
formation is an important contributing mechanism to the anticancer properties of these 
compounds.  Additionally, it has been established that the combination of an anthracycline 
drug and a formaldehyde-releasing pro-drug is synergistic in cancer cell lines, and leads to 
apoptosis independently of topoisomerase II-mediated damage.17-19  
 Daunorubicin can only form one formaldehyde-mediated covalent bond with DNA (a 
N-CH2-N link), whereas, mitoxantrone and pixantrone can potentially form two covalent 
bonds, as they each contain two potentially reactive amine groups.  Mitoxantrone-DNA 
adducts have a half-life of 50 minutes and appear to be formed between the secondary amine 
of one side chain and the N-2 of guanine at a CpG sequence.20  The more recently synthesised 
anthracenedione pixantrone forms DNA adducts 10- to 100-fold more efficiently at CpG sites 
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than mitoxantrone and while the pixantrone-DNA adducts are still labile, they are more stable 
than those formed by mitoxantrone.21  Previously, Phillips, Cutts and co-workers have also 
shown that pixantrone and mitoxantrone form 2-5 fold more covalent adducts at 5'-CpG 
sequences when the cytosine is methylated at the C-5 position.22  The cytosine residue in CpG 
sequences (found disproportionately in regulatory promoter regions) is often methylated, with 
methylation typically occurring after DNA replication.23  
 
 
Figure 1. Structure of daunorubicin, mitoxantrone, pixantrone and WEHI-150.  The 
atom numbering of WEHI-150 is also given.  
 
A bis-amino mitoxantrone analogue, named herein WEHI-150 (see Figure 1), was 
synthesised in an attempt to develop anthracenedione analogues that are more reactive with 
DNA than mitoxantrone and pixantrone, but are also more likely to form covalent cross-links 
between the two DNA strands, through the formation of an adduct with a covalent bond to a 
guanine residue on each strand of the duplex.24,25  By the replacement of the terminal 
hydroxyl group on each mitoxantrone side chain with an amine group, it was hypothesised 
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that WEHI-150 would be able to rapidly form covalent linkages with DNA and more 
importantly, it would be able to form multiple covalent linkages with DNA.  DNA sequence 
specific in vitro transcription studies revealed probable interstrand cross-linking sites for 
WEHI-150.25 
 In this study we have examined by mass spectrometry and HPLC the ability of WEHI-
150 to form covalent adducts with oligonucleotides that contain either a CpG or a 5-
methylated cytosine in the CpG (5MeCpG) site.  As the results indicated that WEHI-150 
readily forms multiple covalent adducts with DNA, and to a significantly greater extent when 
the oligonucleotide contains a 5MeCpG site, we have also examined the reversible intercalative 
binding of WEHI-150 at both CpG and 5MeCpG sites by NMR spectroscopy and molecular 
modelling.  The mode of reversible binding of WEHI-150 at the CpG sequence (i.e. from the 
major or minor groove), will affect the rate of adduct formation with the guanine N-2 amino 
group that is located in the minor groove.  It has been established by x-ray studies that 
daunorubicin intercalates at CpG sites from the DNA minor groove,26 whereas, mitoxantrone 
and pixantrone bind from the major groove.27,28  However, in the NMR study of the binding 
of pixantrone to the octanucleotide d(ACGATCGT)2 some non-intercalative minor groove 
binding was also observed.  It was proposed that this small population of minor groove bound 




Oligonucleotides were obtained from GeneWorks, South Australia.  D2O (99.9% D) was 
obtained from Cambridge Isotope Laboratories, and CM-Sephadex from Amersham-
Pharmacia-Biotech.  Formaldehyde (37% solution) was purchased from Sigma-Aldrich (St 
Louis, USA).  Ammonium acetate (NH4OAc), acetonitrile (ACN, HPLC grade) and ammonia 
were obtained from Ajax Finechem (Seven Hills, Australia), while methanol was obtained 
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from Aldrich chemical company.  De-ionised Milli-Q water was used for all the experiments.  
Pixantrone (BBR 2778) was kindly supplied by CTI BioPharma, Seattle, while mitoxantrone 
and daunorubicin were purchased from Sigma-Aldrich.  WEHI-150 was synthesised as 
previously described.29   
 
Sample preparation for mass spectrometry 
A d(ACGCGCGT)2 solution (1 mM) was obtained by annealing the appropriate amounts of 
the self-complementary oligonucleotide in 100 mM ammonium acetate, pH 7.5, by heating to 
90 °C for 15 min and then allowing the sample to cool slowly to room temperature.  Drug 
stock solutions were prepared by dissolving the appropriate amount in 100 mM ammonium 
acetate to obtain a final concentration of 1 mM.  All stock solutions were stored at -20 °C 
until required for experiments.  DNA-drug cross-linking samples were prepared by adding the 
appropriate amount of double-stranded DNA (1 mM stock) and drug (1 mM stock) to obtain a 
1:5 molar ratio with a final DNA concentration of 40 µM in 100 mM ammonium acetate.  
Solutions were left to equilibrate for one hour, then formaldehyde was added to the DNA-
drug mixture to obtain a formaldehyde concentration of 2 mM.  Samples were incubated at 
room temperature (21 °C) for six hours and then 10 µL of the mixture was taken and diluted 




All drug-DNA complexes were analysed under the same instrumental conditions using a 
Waters Q-Tof Ultima™ ESI mass spectrometer equipped with a Z-spray ionisation source and 
a quadrupole mass analyser with a m/z range of 32,000.  Samples were injected into the mass 
spectrometer at a flow rate of 20 µL/min using a Harvard Model 22 syringe pump (Natick, 
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MA, USA).  All spectra were acquired using a MCP potential of 1850V, Rf lens energy of 
70V, capillary voltage of 2.50 kV and sampling and extraction cone voltages were 70V and 4 
V, respectively.  The source temperature was 80 °C and the desolvation gas flow rate was 300 
L/h at a temperature of 120 °C.  All spectra were acquired in negative ion mode over the 
range m/z 500-4000 and typically 30 acquisitions were combined to obtain a representative 
spectrum.  Each spectrum was then background subtracted using a polynomial order of 2 with 
20% below curve, then smoothed using the MassLynx software, where 10 channels were 
smoothed twice.  Prior to analysis the instrument was externally calibrated with a solution of 
1 mg/mL caesium iodide (CsI) over the m/z acquisition range. 
 
Sample preparation for HPLC 
Oligonucleotides solutions (20 µΜ) were incubated with WEHI-150 (40 µΜ) and 
formaldehyde (2 mM) in 100 mM ammonium acetate pH 6.8 at 37 °C for 10 hours, then the 
un-reacted (including the reversibly bound) WEHI-150 was removed by phenol/chloroform 
extraction and the DNA precipitated by the addition of absolute ethanol.  The WEHI-150-
DNA adducts, a blue precipitate, were dissolved in 100 mM ammonium acetate pH 6.8 prior 
to injection into the HPLC.  
 
HPLC 
HPLC analysis was performed on a Shimadzu prominence (UFLC) instrument, consisting of 
an auto sampler (SIL-20AHT), pump (LC-20AD) and PDA detector (SPD-M20A).  UV/Vis 
detection, 260 nm for DNA and 660 nm for the WEHI-150, was used.  The reaction between 
WEHI-150 and the oligonucleotide was monitored by HPLC where mobile phase A was 0.1% 
TEA in water pH 7 adjusted with acetic acid and mobile phase B was HPLC grade acetonitrile 
with 10% water.  A C18 column, 4.6 x 150 mm, 5 micron, reverse phase (Alltech Apollo) was 
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used at room temperature at a flow rate of 1.0 mL/min. The chromatography gradient elution 
was: 0 min, 0% B; 30 min, 30% B; 40 min, 50% B; 50 min, 50% B.  
 
Sample preparation for NMR  
Oligonucleotides were purified from minor impurities by passing them through a C18 Sep-
Pak cartridge and then converted to the sodium salt using a CM-Sephadex C-25 ion exchange 
resin column, as previously described.30  The oligonucleotide was dissolved in 650 µL of 
phosphate buffer (pH 7.0), containing 20 mM NaCl and 1 mM Na2H2EDTA, and the solution 
was freeze-dried.  Finally the oligonucleotide was dissolved in 650 µL of 99.9% D2O and the 
solution heated to 90 °C and then cooled slowly to achieve the most stable duplex 
conformation prior to use.  The concentration of the oligonucleotide was estimated by the UV 
absorbance (at A260), using an extinction coefficient of 6,600 M-1cm-1 per nucleotide.  Stock 
solutions of WEHI-150 were prepared in 99.9% D2O, and directly added to the NMR tube 
containing the oligonucleotide and the 1H NMR spectrum recorded. 
 
NMR Spectroscopy 
NMR experiments were recorded at 400 MHz for the 1H nuclei using a Varian Unityplus-400 
spectrometer at 25 °C unless otherwise stated and the data processed using the Agilent 
software Vnmrj 2.2C.  Chemical shift values were referenced to HDO at 4.78 ppm relative to 
2,2-dimethylsilapentane-5-sulfonic acid.  One- and two-dimensional spectra were recorded in 
99.9% D2O for the non-exchangeable protons whereas for the exchangeable protons, spectra 
were recorded in 90% H2O/10% D2O using the WET solvent suppression technique.  Phase-
sensitive NOESY spectra were acquired using the method of States et al.,31 with 2048 data 
points in t2 and 256 in t1 values with pulse repetition delay of 1.7 s for mixing time ranging of 
100 and 300 ms.  DQFCOSY spectra were recorded using the same t2, t1 and pulse repetition 
delay as stated above.  
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Molecular modelling 
Molecular modelling was performed using HyperChem 7.5 software.  Double helix B type 
oligonucleotide was generated from the nucleic acid database and energy restraints were 
added to preserve the hydrogen bonding between base pairs expected of duplex DNA during 
the optimisation procedure, which were conducted in vacuo using the Amber 99 force field 
and a Polak-Ribiere conjugant-gradient algorithm with 5 x 10-5 kcal/(Å mol) convergence 
criteria.  
The point charges of WEHI-150 were determined from semi-empirical calculations 
using the AM1 program.  The WEHI-150 complex point charges resulting from different 
AM1 calculations appeared to vary only slightly with the conformation.  Therefore, the point 
charges resulting from an optimised confirmation were used to approximate the charges for 
the subsequent molecular modelling AMBER optimisations with the DNA oligonucleotide. 
The compound was manually inserted into the free DNA model to reflect the intermolecular 
NOEs observed with DNA protons.  Energy restraints were applied to preserve the observed 
intermolecular NOEs and base pair hydrogen bonds during the subsequent interactive 
optimization using AMBER and then the restraints were removed to confirm the resulting 
structure was an energy minimised structure.  
 
Results  
Mass spectrometry analysis of covalent binding 
Mass spectrometry was used to identify drug-oligonucleotide complexes, both reversibly 
bound and covalent adducts, for WEHI-150 and the control anthracenedione drugs 
daunorubicin, mitoxantrone and pixantrone.  Preliminary experiments indicated that under the 
conditions used the hexanucleotide sequence d(CGCGCG)2 was not stable in the gas phase 
and mostly separated into its single strands, with only small amounts of the free and drug-
bound duplex being observed. Consequently, to increase duplex stability and the intensity of 
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the observed drug-DNA adducts the octanucleotide d(ACGCGCGT)2 was used for the mass 
spectrometry experiments.  For the covalent adducts, it was possible to determine the number 
of covalent CH2 links each drug formed with the oligonucleotide.  Ionisation by electrospray 
produces a range of charge states for oligonucleotides as a function of the sequence and 
length, and for d(ACGCGCGT)2 the charge states of 4- and 3- were observed as the most 
abundant species in the spectrum under the conditions used.  While it was noted that some  
drug-DNA adducts contained one and two bound drugs, and a very small proportion 
contained three bound drugs (spectra not shown), the nature of the DNA used (a self-
complementary sequence) created peak overlap for some of the charge states (single- versus 
double-stranded).  Although the resolution obtained in each spectrum allows determination of 
the exact number of covalent CH2 links each adduct formed with the oligonucleotide, it was 
not possible to unambiguously attribute the proportion of CH2 cross-links made to the 
oligonucleotide for each drug when more than one drug was bound.  In order to avoid any of 
these issues, the 3- charge state was examined in detail, with a focus on the duplex with only 
one drug, either reversibly or covalently bound.  Table 1 shows that the obtained m/z values 
for the drug-oligonucleotide complexes containing one bound drug were in agreement with 













Table 1. Calculated and experimental m/z values for reversible and covalent drug-DNA 
complexes for d(ACGCGCGT)2 with one drug bound for the 3- charge state.  




Figure 2 shows the 1700 to 1820 m/z region of the mass spectra of the drug-
oligonucleotide complexes after a 6-hour incubation with formaldehyde.  Control experiments 
were conducted to determine the effect of the addition of 2 mM formaldehyde to the 
oligonucleotide in the absence of drug.  No significant changes were observed in the mass 
spectrum, indicating that formaldehyde did not react with the oligonucleotide (data not 
shown).  As observed in Figure 2, the bulk of the single bound daunorubicin existed as a 
covalent adduct containing one covalent link to the oligonucleotide.  This is the expected 
result, as daunorubicin contains only one amine group; however, of note is the almost absence 
of any reversibly bound daunorubicin.  For mitoxantrone, only a relatively small proportion of 
the bound drug is covalently linked to the oligonucleotide, with the reversibly bound species 
dominating.  While mitoxantrone is theoretically capable of forming adducts with two 
covalent links to the oligonucleotide, only adducts with one covalent linkage were observed.  
Similar results were observed for pixantrone, although the proportion of the covalent adduct 
[DNA] 3- 
















































was significantly greater.  Interestingly, the profile for WEHI-150 was different to that of the 
other drugs.  Although not to the same degree as observed with daunorubicin, the proportion 
of covalently bound oligonucleotide adducts was greater than that of the reversibly bound 
WEHI-150.  Furthermore, adducts with one, two and even three covalent links to the 










Figure 2.  Mass spectra showing the adducts formed after a 6-hour incubation at room 
temperature of d(ACGCGCGT)2 with daunorubicin (A), mitoxantrone (B), 
pixantrone (C) and WEHI-150 (D) in the presence of formaldehyde at 1:5 ratio 
of DNA duplex to drug with [DNA= 5 µM].  The spectra show the 1770-1820 
m/z region where the drug-DNA adducts charge state is 3- with one bound 
drug.  Numbered empty shapes () indicate the number of CH2 cross-links 
formed between the double stranded DNA and the drug.  Zero indicates 
reversible binding by the drug. Note: peaks around m/z 1740 in (A) correspond 
at 2 drugs for single stranded 2- charge state with m/z 1737 = 1 CH2 and m/z 




HPLC analysis of covalent binding 
While the results from the mass spectrometry experiments demonstrated that WEHI-150 
could form one, two or three covalent bonds with d(ACGCGCGT)2, it was not possible to 
determine the extent of the covalent adducts that were formed relative to unreacted and 
reversibly-bound oligonucleotide.  Consequently, HPLC was used to examine the extent of 
covalent bond formation of WEHI-150 with d(CGCGCG)2 and d(CG5MeCGCG)2.   Figure 3 
shows the HPLC elution profiles of the oligonucleotide mixtures obtained after WEHI-150 
was incubated with either d(CGCGCG)2 or d(CG5MeCGCG)2 in the presence of formaldehyde 
and then repeatedly extracted with a phenol/chloroform solution before being precipitated by 
the addition of ethanol.  With d(CGCGCG)2, three approximately equal small product peaks 
(1', 2' and 3') were observed in the HPLC profile, along with a large peak for the free 
oligonucleotide.  Virtually all non-covalently bound WEHI-150 was removed by the 
phenol/chloroform extraction after the incubation of the drug with the oligonucleotide.  In 
addition, any remaining small amount of reversibly bound drug dissociates from the 
oligonucleotide on the HPLC column and is separately eluted after the three small peaks seen 
in Figure 3, at approximately 27 minutes.  Consequently, the observed small peaks can be 
identified as covalent adducts due to their characteristic WEHI-150 UV/Vis absorption at 660 
nm.  By contrast, incubation of WEHI-150 with d(CG5MeCGCG)2 in the presence of 
formaldehyde resulted in the formation of a significantly greater amount of covalent adducts.  
Of further note, only one major covalent adduct was observed in the HPLC elution profile, 










Figure 3.   HPLC elution profiles of the oligonucleotide mixture obtained after incubation 
with WEHI-150 in the presence of formaldehyde. A: d(CGCGCG)2, where the 
free DNA peak is denoted as 1 and the WEHI-150-DNA covalent adducts 1', 2' 
and 3'.  B: d(CG5MeCGCG)2, where the free oligonucleotide peak is denoted as 











NMR analysis of reversible binding at CpG and 5MeCpG sites 
As the HPLC experiments indicated that WEHI-150 formed significantly more covalent 
adducts with d(CG5MeCGCG)2 than with the corresponding non-methylated oligonucleotide in 
the presence of formaldehyde, an NMR study of the reversible interaction of the drug at both 
CpG and 5MeCpG sites was undertaken.  In order to simplify the analysis of the binding of 
WEHI-150 at a CpG site, the octanucleotide d(ACGGCCGT)2 was used for the NMR 
experiments.  The octanucleotide contains two symmetric CpG sites (indicated in bold), rather 
than the three potential CpG binding sites in d(CGCGCG)2.  However, for the analysis of 
WEHI-150 binding at a 5MeCpG site, the hexanucleotide d(CG5MeCGCG)2 was used, as this 
oligonucleotide also allowed a comparison of the relative preference for a 5MeCpG compared 
to the non-methylated dinucleotide. 
 
Assignment of free WEHI-150 
The aromatic protons in the 1H NMR spectrum of WEHI-150 were assigned using standard 
one-dimensional COSY and NOESY NMR experiments and by comparison with the 
previously reported assignments for mitoxantrone and pixantrone.28,32  The H6,7 protons were 
assigned by the observation of a strong NOE to the Ha protons and weak NOEs to the Hb, Hc 
and Hd protons.  
 
WEHI-150 binding to d(ACGGCCGT)2 
 
The resonances in the 1H NMR spectra of the free and WEHI-150 bound oligonucleotide 
were assigned by standard techniques.33-35  Consistent with many NMR studies of 
oligonucleotides,33-36 the analysis of short mixing-time NOESY and DQFCOSY spectra 
indicated that the octanucleotide adopted a B-type conformation in the aqueous buffer.   
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Figure 4 shows the spectra of the imino protons for the free and WEHI-150-bound 
d(ACGGCCGT)2 at 10 oC.  Two new sets of peaks, corresponding to 1:1 and 2:1 drug to 
oligonucleotide duplex binding, were observed upon addition of WEHI-150 to the 
oligonucleotide.  This indicates that WEHI-150 binds the oligonucleotide with slow exchange 
kinetics (on the NMR time scale).  The observation of only three imino resonances at a drug 
to oligonucleotide ratio of 2 indicates that the two WEHI-150 molecules were bound to 
d(ACGGCCGT)2 in a symmetrical fashion, suggesting selective binding at the two CpG sites.  
Significant upfield shifts were observed for the imino resonances from the G3 and G7, again 
consistent with intercalation at both the C2pG3 and C6pG7 sites.  Two new sets of peaks from 
the aromatic protons of d(ACGGCCGT)2 were also observed upon addition of WEHI-150 to 
the oligonucleotide (see Figure 5).  Table 2 summarises the chemical shifts of the resonances 
from the WEHI-150-bound oligonucleotide and the change in chemical shift upon addition of 
WEHI-150 to a drug to duplex ratio of 2.  The resonances from the WEHI-150 protons shifted 
upfield (0.24 to 0.35 ppm, see Table 3), consistent with WEHI-150 binding by intercalation, 







Figure 4.   1H NMR spectrum of the imino resonances of d(A1C2G3G4C5C6G7T8)2 (A) and 
with added WEHI-150, at a drug to duplex ratio R = 0.8 (B), R = 1.4 (C) and R 
=1.9 (D) at 10 °C, in 90%/10% H2O/D2O in pH 7 phosphate buffer.   In the 





Figure 5.    1H NMR spectra of the titration of d(A1C2G3G4C5C6G7T8)2 with WEHI-150. 
(A) free oligonucleotide, (B) with added WEHI-150 to DNA duplex ratio (R) 
of 0.8 (C) with added WEHI-150 at R = 1.4 (aromatic region). In the spectra, * 
represents 1:1 drug to oligonucleotide binding, while # indicates 2:1 binding. 
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Table 2.   1H NMR assignment of the resonances of d(A1C2G3G4C5C6G7T8)2 with added 
WEHI-150 at R = 2, at 25 °C in pH 7 phosphate buffer. * Imino proton shifts 
were recorded at 10 °C. Changes in chemical shift upon WEHI-150 binding 

















Table 3.  1H NMR shifts of free WEHI-150 and WEHI-150 bound to d(ACGGCCGT)2 
and d(CG5MeCGCG)2 at drug to DNA ratios (R) = 2 and 1, respectively, in pH 
7 phosphate buffer.  Changes in chemical shift are given in brackets, with a 
negative sign indicating an upfield shift.  
 
 
Base H8/H6 AH2/CH5 H1' H2' H2'' Methyl Imino* 
A1 
8.25 7.95 6.21 2.62 2.80     (+0.05) (-0.09) (-0.01) (0.00) (+0.06) 
C2 
7.44 5.36 5.42 2.09 2.36     (+0.01) (-0.14) (+0.01) (-0.01) (-0.01) 
G3 
8.09   5.86 2.73 2.73  
12.63 




5.81 2.60 2.60   13.04 (-0.09) (-0.14) (-0.01) (-0.14) (+0.02) 
C5 
7.39 5.17 5.88 2.08 2.47     (+0.01) (-0.13) (-0.09) (0.00) (-0.01) 
C6 
7.52 5.57 5.63 1.93 2.27     (+0.10) (-0.03) (0.00) (+0.01) (-0.07) 
G7 
8.27   6.09 2.70 2.36   12.41 (+0.27) (-0.03) (-0.04) (-0.38) (-0.53) 
T8 
7.49   6.28 2.26 2.65 1.37   (+0.04) (+0.02) (-0.01) (+0.38) (-0.32)   
WEHI-150 
protons H2,3 H6,7 Ha Hb Hc Hd 






























NOESY spectra were recorded to obtain a detailed picture of the WEHI-150-
oligonucleotide binding.  Strong intermolecular NOEs were observed from the WEHI-150 
H2,3 to the H1' protons of G3 and G7 and from the H6,7 protons to the H5 protons of C2 and 
C6 (see Figure 6).  In addition, weak NOEs were also observed from the H6,7 protons of the 
WEHI-150 to the H6 protons of C2 and C6.  These NOEs indicate that WEHI-150 
preferentially binds at the CpG sites of the oligonucleotide as expected.  Furthermore, NOEs 
between the ethylene side chain protons of WEHI-150 and the major groove protons of the C2 
and C6 were also observed.  Taken together, the observed pattern of intermolecular NOEs 




Figure  6.   An expansion of a NOESY spectrum of d(A1C2G3G4C5C6G7T8)2 with added 
WEHI-150, at a ratio of R = 0.8  to DNA at 20 °C. It shows the NOE 
connectivities from the aromatic protons C2H5, C6H5 and G3, G7 sugar H1' 





WEHI-150 binding to d(CG5MeCGCG)2 
The addition of WEHI-150 to d(CG5MeCGCG)2 induced an upfield shift for the G4 imino 
resonance (see Figure 7), suggesting that WEHI-150 bound at the 5MeCpG site.  Significant 
upfield shifts (0.59 to 0.70 ppm, see Table 3) were observed from the WEHI-150 aromatic 
protons upon addition to d(CG5MeCGCG)2, consistent with WEHI-150 binding by 
intercalation.  Interestingly, the resonances from the Ha and Hb aliphatic side chain protons 
also shifted considerably upfield.  While the aromatic resonances from the oligonucleotide 
generally broadened upon addition of WEHI-150, multiple peaks for the H6 of the 5MeC3 were 






Figure 7.  1H NMR spectra of the imino resonances of the d(C1G25MeC3G4C5G6)2 A, with 
added WEHI-150 at R = 1 B, at 10 °C in 90%/10% H2O/D2O in pH 7 
phosphate buffer. G2 and G4 imino protons of the free and bond 






Table 4 1H NMR assignment of the resonances of d(C1G25MeC3G4C5G6)2 with added 
WEHI-150 at R = 1 in pH 7 phosphate buffer at 30 °C. * Imino proton shifts 
were recorded at 10 °C. Changes in chemical shift upon WEHI-150 binding 
are given in brackets, with a negative sign indicating an upfield shift. 





























































































Figure 8.   Aromatic region of the 1H NMR spectrum of free d(CG5MeCGCG)2 (A) and with 
added WEHI-150 at 30 °C in 10 mM phosphate buffer pH 7.0, at a drug to duplex 
ratio (R) of 0.25 (B), (C) R = 0.37, (D) R = 0.5, (E) R = 1.0, free WEHI-150 (F). 
The H8 and H6 protons of the hexanucleotide and the H2,3 and H6,7 protons of 
the free and bound WEHI-150 are indicated.  
 
 
Figure 9 shows an expansion of a NOESY spectrum of d(CG5MeCGCG)2 with added 
WEHI-150.  An intermolecular NOE was observed between the WEHI-150 H2,3 protons to 
the H2" proton of the 5MeC3.  In addition, NOEs were also observed from the WEHI-150 
aliphatic protons to the H1' proton of G4. These unambiguous NOEs indicate that WEHI-150 
predominantly intercalates via the minor groove at the 5MeCpG site.  However, additional 
weak NOEs were also observed from WEHI-150 aliphatic protons to the H8 and H6 protons 
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of the G4 and 5MeC3 protons, indicating that some proportion of WEHI-150 also intercalates 
via the major groove.  
 
 
Figure 9.   An expansion of a NOESY spectrum of d(CG5MeCGCG)2 with added 
WEHI-150, at a drug to DNA duplex ratio of 1, at 35 °C in D2O and pH 7 
phosphate buffer.  The expansion shows the NOE connectivities from the 
WEHI-150 H2,3 and Ha, Hc and Hd protons (3.1-3.45 ppm) to the 
octanucleotide H2" of the 5MeC3 and H1' of the G4 protons respectively. 
 
Molecular modelling  
Mass spectrometry indicated that WEHI-150 could form multiple covalent bonds with a 5'-
GCGC duplex sequence, and NMR studies indicated that covalent bond formation occurred 
when the drug predominantly intercalated from the minor groove.  Due to the broad and 
overlapping resonances from the two binding forms, the NMR data did not allow the 
determination of a quantitative structure of WEHI-150 intercalated at the 5'-5MeCpG site of 
d(CG5MeCGCG)2.  However, simple HyperChem binding models were constructed to examine 
the feasibility of WEHI-150 forming two to four covalent bonds with the four guanine 
residues in a 5'-G5MeCGC duplex sequence.  Molecular models were constructed (see Figure 
	 26	
10) with the WEHI-150 intercalated (non-covalently bound) from the minor groove at the 5'-
5MeCpG site of the hexanucleotide d(CG5MeCGCG)2.  The WEHI-150-oligonucleotide 
structure is consistent with the intermolecular NOEs observed in the NMR experiments.  
Models were examined where the WEHI-150 was intercalated from the major groove at the 
5'-5MeCpG site; however, the distances between the WEHI-150 and oligonucleotide protons 
that gave NOE cross-peaks in NOESY spectra were significantly greater than the maximum 
distance (5 Å) for which an NOE can be observed.  For example, a strong intermolecular 
NOE was observed between the WEHI-150 aliphatic Ha proton and the G4H1' from 
d(CG5MeCGCG)2: the minimum distance between these protons for the drug intercalated from 
the major groove was 9.25 Å; whereas the distance with WEHI-150 intercalated from the minor 
groove was 3.3 Å.  The model clearly demonstrates that, in principle, WEHI-150 can readily 
form between one and four covalent bonds with the four guanine residues in the 5'-G5MeCGC 
duplex sequence.  Unless the DNA is significantly distorted, the model suggests that when 
WEHI-150 forms three covalent bonds, it must form an interstrand cross-link where each 





Figure 10. Energy minimized HyperChem model of WEHI-150 intercalated (non-
covalently bound) at the 5MeCpG site via the minor groove. The guanine 
residues are shown in yellow, the cytosine residues in grey, guanine NH2 
groups are red, and the DNA backbone in cyan. The WEHI-150 is shown in 




Anthracenedione compounds can bind DNA by intercalation and thereby exert anticancer 
activity through the impairment of topoisomerase II.9,10  However, it has also been proposed 
that anthracenedione drugs containing side chain amine groups can induce apoptosis in cancer 
cells through formation of a covalent adduct with the N-2 amino group of a guanine residue at 
CpG sites after activation by formaldehyde.14-16  The results of this study confirm that 
daunorubicin, mitoxantrone and pixantrone can form covalent adducts with duplex DNA.  
WEHI-150 was synthesised in an attempt to develop anthracenedione analogues that can form 
covalent cross-links between the two DNA strands, through the formation of covalent bonds 
to a guanine residue on each strand of the duplex.  The results from this study indicate that 
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WEHI-150 can form at least three covalent bonds with duplex DNA at GpCpGpC sequences 
after activation by formaldehyde.    
The HPLC results presented in this study demonstrated that WEHI-150 formed 
considerably more covalent adducts with the hexanucleotide d(CG5MeCGCG)2, than with the 
non-methylated hexanucleotide d(CGCGCG)2.  Previous studies have demonstrated a 2-5 
fold increase in covalent adducts with mitoxantrone and pixantrone when the DNA 
contained 5MeCpG sequences.22 As the initial reversible binding of WEHI-150 at a CpG or  
5MeCpG site must to some degree influence the formation of the subsequent covalent bond 
formation, an NMR study of WEHI-150 binding with d(CGCGCG)2 and d(CG5MeCGCG)2 
was carried out.  The results confirmed that WEHI-150 preferentially intercalated at CpG 
sites, and demonstrated that the drug intercalated from the DNA major groove.  This is 
consistent with the results of previous NMR studies with the closely related analogues 
mitoxantrone and pixantrone.27,28  Furthermore, the results demonstrated WEHI-150 
preferentially intercalates at 5MeCpG sites, compared to CpG sites, and of greater 
consequence, the drug predominantly intercalated from the minor groove at 5MeCpG 
sequences.   
Although pixantrone forms more covalent adducts at 5MeCpG sites than at CpG sites, 
previous NMR studies have established that pixantrone predominantly intercalates from the 
major groove at both 5MeCpG sites and CpG sites.28  However, some minor groove binding 
was observed.28  Consequently, it is possible that the additional DNA adducts formed by 
pixantrone at 5MeCpG sites could be due to the increased nucleophilicity of the guanine N-2 
due to the electronic effect of the methylation of the complementary cytosine.  For WEHI-
150, the electronic effects of C-5 methylation may contribute to the increased adducts formed 
at 5MeCpG sites; however, the switching from intercalation from the major groove to the minor 
groove is likely to be more important.  It is not clear why WEHI-150, unlike pixantrone, 
intercalates from the minor groove at 5MeCpG sites.  Examination of molecular models 
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suggests that there are no steric barriers to major groove intercalation at 5MeCpG sites for 
either pixantrone or WEHI-150.  Base stacking is the main driving force for the formation of 
duplex DNA,37 and the stacking between an intercalated drug and the base pairs at the binding 
site also provides favourable thermodynamic driving forces for the formation of the drug-
DNA complex.38 However, DNA groove-binding interactions are predominantly entropy 
driven, and it has been established that intercalation is enthalpically driven.38  Consequently, 
it is likely that the stacking interactions of WEHI-150 are maximised for minor groove 
intercalation at 5MeCpG sites.  In particular, the electrostatic dipole-dipole interactions 
between WEHI-150 and the DNA base pairs are a significant stabilising force for the 
intercalative binding, and play a role in determining the geometry of the binding.  The 
anthracenedione moiety of WEHI-150 produces a different pattern of dipole moments, 
compared to the aza-anthracenedione pixantrone, which consequently results in a different 
binding geometry – minor groove intercalation for WEHI-150, and major groove intercalation 
for pixantrone. 
Taken together, the results of this study demonstrate that WEHI-150 is likely to form 
interstrand DNA cross-links.  Although it is yet to be established, it is possible that the 
interstrand cross-links formed by WEHI-150 would disrupt DNA-mediated processes to a 
greater degree than anthracenedione drugs that are capable of forming only one covalent bond 
with DNA.  Furthermore, the observed reversible binding preference for 5MeCpG sites, 
compared to CpG sites, could also potentiate the anticancer properties of WEHI-150.  Gene 
expression is largely affected by promoters, which often contain CpG “islands”.39  Although 
cancer cells generally contain hypomethylated genomes, CpG islands are hypermethylated.39 
Consequently, preferential binding in the DNA minor groove at the methylated CpG islands 
in promoter regions could allow for the optimal activity of WEHI-150 through the formation 
of covalent bonds with guanine residues after activation by formaldehyde. 
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In conclusion, the results of this study indicate that WEHI-150 can form interstrand 
cross-links with DNA after activation by formaldehyde.  In addition, WEHI-150 
predominantly intercalates from the DNA major groove at CpG sites, but from the minor 
groove at 5MeCpG sequences.  As intercalation at 5MeCpG sites is preferred compared to non-
methylated sites, WEHI-150 forms considerably more covalent adducts at sequences 
containing 5MeCpG sites with adjacent guanine residues. 
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